Imatinib and persistence of leukaemia stem cells
Thursday 3 November 2011
A recent study shows that while imatinib mesylate (IM) treatment reduces the burden of leukaemia stem cells in chronic myelogenous leukaemia (CML) patients, there is selective retention of these cells. The results clearly showed that BCR-ABL+ stem cells persist in CML patients despite prolonged treatment with IM.
>> http://www.oncologystat.com/journals/journal_scans/Persistence_of_Leukemia_Stem_Cells_in_Chronic_Myelogenous_Leukemia_Patients_in_Prolonged_Remission_With_Imatinib_Treatment.html
European Oncology Nursing SocietyAvenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu